Drug | Mechanism | Condition | Number of cases reported |
Ponatinib | Tyrosine kinase inhibitor | Gastrointestinal stromal tumor, chronic myeloid leukemia, acute lymphoblastic leukemia | 98 |
Imatinib | Tyrosine kinase inhibitor | Gastrointestinal stromal tumor | 1 |
Nilotinib | Tyrosine kinase inhibitor | Chronic myeloid leukemia | 1 |
Sorafenib | Multikinase inhibitor | Nonseminomatous germ cell carcinoma | 1 |
NR | PI3K/mTOR inhibitor | Anaplastic oligodendroglioma | 1 |
Idelalisib and ofatumumab | PI3K inhibitor, CD20 inhibitor | Small lymphocytic leukemia | 1 |
Idelalisib | PI3K inhibitor | Small lymphocytic leukemia | 1 |
Telaprevir | Viral protease inhibitor | Hepatitis C virus | 1 |
Sofosbuvir | Viral NS5B protein inhibitor | Hepatitis C virus | 1 |
Imiquimod | TLR7 agonist | Actinic keratosis, superficial basal cell carcinoma | 4 |
NPH insulin | Intermediate-acting insulin | Type 1 diabetes mellitus | 1 |
Ramipril | ACE inhibitor | NR | 1 |
Pembrolizumab | Programmed cell death protein 1 inhibitor | Squamous cell carcinoma | 1 |
Nivolumab | Programmed cell death 1 receptor inhibitor | Hodgkin lymphoma | 1 |
Bevacizumab | Vascular endothelial growth factor inhibitor | Age-related macular degeneration | 1 |
Simvastatin | HMG-CoA reductase inhibitor | Hyperlipidemia | 1 |
Do you want to add Medilib to your home screen?